1. Home
  2. TLSA

as of 11-19-2026 3:59pm EST

$0.68
$0.10
-12.43%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Founded: 2013 Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 145.1M IPO Year: 2017
Target Price: $7.87 AVG Volume (30 days): 522.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.55 - $1.90 Next Earning Date: 05-01-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: